Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZTI-01 PK and Safety Study in Healthy Adults
NCT03910673Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fosfomycin disodium in bacterial infection (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Concentration-time Curve (AUC 0-8) at Day 2, Area Under the Concentration-time Curve (AUC 0-inf) at Day 2 and 8 more. Started Jun 2019; status: completed.
02
Drugs
fosfomycin disodium
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03910673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910673.